June 9, 2019
Marking the culmination of a 33-year odyssey, scientists today report a milestone in type 1 diabetes: the first time the disease has been markedly delayed in young people at high risk. Presenting at the American Diabetes Association meeting in San Francisco, California, and publishing simultaneously in The New England Journal of Medicine (NEJM), researchers found that 2 weeks of an experimental intravenous (IV) drug held off disease by an average of about 2 years.